Flanking bases influence the nature of DNA distortion by Platinum 1,2-intrastrand (GG) cross-links

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Bhattacharyya, Debadeep ^a   Ramachandran, Srinivas ^a,b   Sharma, Shantanu ^a   Pathmasiri, Wimal ^a   King, Candice L ^a   Baskerville Abraham, Irene ^c   Boysen, Gunnar ^c   Swenberg, James A ^b,c   Campbell, Sharon L ^a,b   Dokholyan, Nikolay V ^a,b   Chaney, Stephen G ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; OXALIPLATIN; AMINE; PLATINUM; PLATINUM COMPLEX; PROTON;

ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DNA CONFORMATION; DNA CROSS LINKING; DNA SEQUENCE; DRUG DETERMINATION; DRUG STRUCTURE; HYDROGEN BOND; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN DNA BINDING; BASE PAIRING; CHEMISTRY; CONFORMATION; DRUG EFFECT; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; SOLUTION AND SOLUBILITY; TEMPERATURE;

AMINES; BASE PAIRING; BASE SEQUENCE; DNA ADDUCTS; HYDROGEN BONDING; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; ORGANOPLATINUM COMPOUNDS; PLATINUM; PROTONS; SOLUTIONS; TEMPERATURE;

EID: 80051496112     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023582     Document Type: Article

References (62)

1. Chaney SG, Campbell SL, Bassett E, Wu Y, (2005) Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 53: L3-11.
2. Woynarowski JM, Chapman WG, Napier C, Raymond E, (1997) Oxaliplatin effects on naked and intracellular DNA. Proceedins of the American Association for Cancer Research 38: 311.
3. Page JD, Husain I, Sancar A, Chaney SG, (1990) Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry 29: 1016-1024.
4. Jennerwein MM, Eastman A, Khokhar AR, (1989) Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes. Chem-BiolInteract 70: 39-49.
5. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, et al. (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochemical Pharmacology 52: 1855-1865.
6. Chaney SG, Vaisman A, (1999) Specificity of platinum-DNA adduct repair. J Inorg Biochem 77: 71-81.
7. Wei M, Cohen SM, Silverman AP, Lippard SJ, (2001) Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins. J Biol Chem 276: 38774-38780.
8. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, et al. (1996) The role of mismatch repair in platinum drug resistance. Cancer Res 56: 4881-4886.
9. Zdraveski ZZ, Mello JA, Farinelli CK, Essigmann JM, Marinus MG, (2002) MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA. The Journal of Biological Chemistry 277: 1255-1260.
10. Malina J, Novakova O, Vojtiskova M, Natile G, Brabec V, (2007) Conformation of DNA GG intrastrand cross-link of antitumor oxaliplatin and its enantiomeric analog. Biophysical Journal 93: 3950-3962.
11. Chvalova K, Sari MA, Bombard S, Kozelka J, (2008) LEF-1 recognition of platinated GG sequences within double-stranded DNA. Influence of flanking bases. J Inorg Biochem 102: 242-250.
12. Aebi S, Kurdihaidar B, Gordon R, Cenni B, Zheng H, et al. (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56: 3087-3090.
13. Fink D, Zheng H, Nebel S, Norris PS, Aebi S, et al. (1997) In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Research 57: 1841-1845.
14. Drummond JT, Anthoney A, Brown R, Modrich P, (1996) Cisplatin and adriamycin resistance are associated with MutL alpha and mismatch repair deficiency in an ovarian tumor cell line. The Journal of Biological Chemistry 271: 19645-19648.
15. Nehme A, Baskaran R, Aebi S, Fink D, Nebel S, et al. (1997) Differential induction of c-Jun NH2-terminal kinase and c- Abl kinase in DNA mismatch repair-proficient and deficient cells exposed to cisplatin. Cancer Res 57: 3253-3257.
16. Nehme A, Baskaran R, Nebel S, Fink D, Howell SB, et al. (1999) Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and-deficient cells. British Journal of Cancer 79: 1104-1110.
17. Drotschmann K, Topping RP, Clodfelter JE, Salsbury FR, (2004) Mutations in the nucleotide-binding domain of MutS homologs uncouple cell death from cell survival. DNA Repair (Amst) 3: 729-742.
18. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, et al. (1998) The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58: 3579-3585.
19. Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin ARM, Brown R, (1996) Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 56: 1374-1381.
20. Zhai X, Beckmann H, Jantzen HM, Essigmann JM, (1998) Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. Biochemistry 37: 16307-16315.
21. McAnulty MM, Lippard SJ, (1996) The HMG-domain protein Ixr1 blocks excision repair of cisplatin- DNA adducts in yeast. MutatRes-DNARepair 362: 75-86.
22. Huang JC, Zamble DB, Reardon JT, Lippard SJ, Sancar A, (1994) HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci U S A 91: 10394-10398.
23. Vaisman A, Lim SE, Patrick SM, Copeland WC, Hinkle DC, et al. (1999) Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. Biochemistry 38: 11026-11039.
24. Voland C, Bord A, Peleraux A, Penarier G, Carriere D, et al. (2006) Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther 5: 2149-2157.
25. Treiber DK, Zhai X, Jantzen HM, Essigmann JM, (1994) Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc Natl Acad Sci U S A 91: 5672-5676.
26. Jung Y, Lippard SJ, (2003) Nature of Full-Length HMGB1 Binding to Cisplatin-Modified DNA. Biochemistry 42: 2664-2671.
27. He Q, Ohndorf UM, Lippard SJ, (2000) Intercalating residues determine the mode of HMG1 domains a and B binding to cisplatin-modified DNA. Biochemistry 39: 14426-14435.
28. Dunham SU, Lippard SJ, (1997) DNA sequence context and protein composition modulate HMG- domain protein recognition of ciplatin-modified DNA. Biochemistry 36: 11428-11436.
29. Cohen SM, Jamieson ER, Lippard SJ, (2000) Enhanced binding of the TATA-binding protein to TATA boxes containing flanking cisplatin 1,2-cross-links. Biochemistry 39: 8259-8265.
30. Obmolova G, Ban C, Hsieh P, Yang W, (2000) Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA. Nature 407: 703-710.
31. Natrajan G, Lamers MH, Enzlin JH, Winterwerp HH, Perrakis A, et al. (2003) Structures of Escherichia coli DNA mismatch repair enzyme MutS in complex with different mismatches: a common recognition mode for diverse substrates. Nucleic Acids Res 31: 4814-4821.
32. Sixma TK, (2001) DNA mismatch repair: MutS structures bound to mismatches. Current Opinion in Structural Biology 11: 47-52.
33. Yang W, (2008) Structure and mechanism for DNA lesion recognition. Cell Res 18: 184-197.
34. Travers A, (2000) Recognition of distorted DNA structures by HMG domains. Curr Opin Struct Biol 10: 102-109.
35. Churchill ME, Klass J, Zoetewey DL, (2010) Structural analysis of HMGD-DNA complexes reveals influence of intercalation on sequence selectivity and DNA bending. J Mol Biol 403: 88-102.
36. Love JJ, Li X, Case DA, Giese K, Grosschedl R, et al. (1995) Structural basis for DNA bending by the architectural transcription factor LEF-1. Nature 376: 791-795.
37. Werner MH, Huth JR, Gronenborn AM, Clore GM, (1995) Molecular basis of human 46X,Y sex reversal revealed from the three- dimensional solution structure of the human SRY-DNA complex. Cell 81: 705-714.
38. Werner MH, Bianchi ME, Gronenborn AM, Clore GM, (1995) NMR spectroscopic analysis of the DNA conformation induced by the human testis determining factor SRY. Biochemistry 34: 11998-12004.
39. Murphy EC, Zhurkin VB, Louis JM, Cornilescu G, Clore GM, (2001) Structural basis for SRY-dependent 46-X,Y sex reversal: modulation of DNA bending by a naturally occurring point mutation. J Mol Biol 312: 481-499.
40. Ohndorf U-M, Rould MA, He Q, Pabo CO, Lippard SJ, (1999) Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature 399: 708-712.
41. Gelasco A, Lippard SJ, (1998) NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) dGpG intrastrand cross-link, the major adduct of the anticancer drug cisplatin. Biochemistry 37: 9230-9239.
42. Spingler B, Whittington DA, Lippard SJ, (2001) 2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex. Inorg Chem 40: 5596-5602.
43. Herman F, Kozelka J, Stoven V, Guittet E, Girault JP, et al. (1990) A d(GpG)-platinated decanucleotide duplex is kinked An extended NMR and molecular mechanics study. European Journal of Biochemistry 194: 119-133.
44. Yang D, van Bloom SSGE, Reedijk J, van Bloom JH, Wang AHJ, (1995) Structure and isomerization of an intrastrand cisplatin-cross-linked octamer DNA duplex by NMR analysis. Biochemistry 34: 12912-12920.
45. Wu Y, Bhattacharyya D, King CL, Baskerville-Abraham I, Huh SH, et al. (2007) Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: Comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link. Biochemistry 46: 6477-6487.
46. Wu Y, Pradhan P, Havener J, Boysen G, Swenberg JA, et al. (2004) NMR solution structure of an oxaliplatin 1,2-d(GG) intrastrand cross-link in a DNA dodecamer duplex. J Mol Biol 341: 1251-1269.
47. Marzilli LG, Saad JS, Kuklenyik Z, Keating KA, Xu Y, (2001) Relationship of solution and protein-bound structures of DNA duplexes with the major intrastrand cross-link lesions formed on cisplatin binding to DNA. J Am Chem Soc 123: 2764-2770.
48. Takahara PM, Frederick CA, Lippard SJ, (1996) Crystal structure of the anticancer drug cisplatin bound to duplex DNA. J Am Chem Soc 118: 12309-12321.
49. Teletchea S, Skauge T, Sletten E, Kozelka J, (2009) Cisplatin adducts on a GGG sequence within a DNA duplex studied by NMR spectroscopy and molecular dynamics simulations. Chemistry 15: 12320-12337.
50. Todd RC, Lippard SJ, (2010) Structure of duplex DNA containing the cisplatin 1,2-{Pt(NH3)2}2+-d(GpG) cross-link at 1.77 A resolution. J Inorg Biochem 104: 902-908.
51. Packer MJ, Dauncey MP, Hunter CA, (2000) Sequence-dependent DNA structure: tetranucleotide conformational maps. J Mol Biol 295: 85-103.
52. Sharma S, Gong P, Temple B, Bhattacharyya D, Dokholyan NV, et al. (2007) Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics. J Mol Biol 373: 1123-1140.
53. Ramachandran S, Temple BR, Chaney SG, Dokholyan NV, (2009) Structural basis for the sequence-dependent effects of platinum-DNA adducts. Nucleic Acids Res 37: 2434-2448.
54. Lavery R, Sklenar H, (1996) Curves 5.1: Helical Analysis of Irregular Nucleic Acids. Institut de Biologie PhysicoChimique.
55. Press WH, Flannery BP, Teukolsky SA, Vetterling WT, (1992) Numerical Recipes in C: The Art of Scientific Computing Cambridge Cambridge University Press.
56. Lavery R, Skelnar H, (1989) Defining the structure of irregular nucleic acids: Conventions and principles. Journal of Biomolecular Structure and Dynamics 6: 655-667.
57. Lavery R, Sklenar H, (1988) The definition of generalized helicoidal parameters and of axis curvature for irregular nucleic acids. Journal of Biomolecular Structure and Dynamics 6: 63-91.
58. Wu Y, Bhattacharyya D, King CL, Baskerville-Abraham I, Huh SH, et al. (2007) Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link. Biochemistry 46: 6477-6487.
59. Cohen SM, Mikata Y, He Q, Lippard SJ, (2000) HMG-domain protein recognition of cisplatin 1,2-intrastrand d(GpG) cross-links in purine-rich sequence contexts. Biochemistry 39: 11771-11776.
60. Eastman A, (1986) Reevaluation of the interactions of cis-diamminedichloro(ethylenediamine)platinum(II) with DNA. Biochemistry 25: 3912-3915.
61. Gruschus JM, Ferretti JA, (1998) 15N-edited three-dimensional NOESY-HMQC with water flipback: enhancement of weak labile 1H resonances of protein side chains contacting DNA. J Magn Reson 135: 87-92.
62. Wuthrich K, (1986) NMR of proteins and nucleic acids. New York Wiley.